BRAF and ovarian clear cell cancer: Nonetheless, dab-SiR activity correlated with dabrafenib activity in a cytotoxicity assay across BRAF-mutant cancer cell lines (R2 = 0.98; Fig. 2C), including melanoma lines SK-MEL-28 and A375, the dabrafenib-resistant derivative A375R, and the ovarian clear cell carcinoma cell line ES2 as a model nonmelanoma BRAF-mutant cell line that is suitable for in vivo microscopy studies.